AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies

Amendment history

The 50 most recent of 67 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

1. Aug 21, 2026

   Minor

   Study Status, Study Description

   Re-verified, no change to tracked fields

   v67

2. May 27, 2026

   Minor

   Completion date: Dec 31, 2025 to Mar 26, 2027

   Study Status · v66

3. Nov 12, 2025

   Minor

   3 amendments

   3 re-verifications since 2025-05-05, no change to tracked fields

   v63-v65

4. Jan 20, 2025

   Minor

   Completion date: Dec 31, 2024 to Dec 31, 2025

   Study Status, References · v62

5. Nov 20, 2024

   Notable

   Primary endpoints: 1 to 5

   Eligibility criteria expanded, about 5 words; Secondary endpoints: 1 to 44; Study title revised; and 1 more

   Show all 5 changes in this update

   • Notable Primary endpoints: 1 to 5
     Show what changed

     To assess the pharmacokineticsNumber of theParticipants solidWith doseAbnormal formClinical Laboratory Parameters Reported as TEAEs in Part A and Part B Number of AZD6244Participants With Abnormal Echocardiogram (ECHO) Parameters Reported as TEAEs in Part A and Part B Number of Participants With Abnormal Electrocardiogram (ECG) Parameters Reported as TEAEs in Part A and Part B Number of Participants With Abnormal Vital Signs Reported as TEAEs in Part A and Part B Nu [...]
   • Minor Eligibility criteria expanded, about 5 words
     Show what changed

     Inclusion Criteria: cancer which is refractory to standard therapies World Health Organization (WHO) performance status 0- to 2 evidence of post-menopausal status or negative pregnancy t [...]
   • Minor Secondary endpoints: 1 to 44
     Show what changed

     ToMaximum assessPlasma safetyConcentration and tolerability of solid dose form(Cmax) of AZD6244 (Part A) Cmax of AZD6244 (Part B Single Dose) Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC) of AZD6244 (Part A) Area Under the Plasma Concentration-time Curve From Time Zero to 12 Hours Post Dose (AUC[0-12]) of AZD6244 (Part A) AUC of AZD6244 (Part B Single Dose) A [...]
   • Minor Study title revised
     Show what changed

     AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in PatientsParticipants With Advanced Solid Malignancies
   • Minor Study arms: 1 to 6

   Study Identification, Study Status, Oversight, Study Description, Study Design, Arms and Interventions, Outcome Measures, Eligibility · v61

• Stopped: an ongoing trial was terminated, suspended or withdrawn.
• Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
• Minor: routine progress and housekeeping, such as sites added or enrollment closed.